Atlas Trials

Exelixis

55 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Exelixis

RecordFirmDate
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease (NCT07750158)Exelixis2026-08-06
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (NCT07620574)Exelixis2026-07-30
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (NCT07428616)Exelixis2026-05-21
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors (NCT07123103)Exelixis2025-08-18
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT06943755)Exelixis2025-07-21
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) (NCT06962332)Exelixis2025-05-13
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors (NCT06952010)Exelixis2025-05-01
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT06630247)Exelixis2024-10-17
Study of XB010 in Subjects With Solid Tumors (NCT06545331)Exelixis2024-08-06
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06082167)Exelixis2024-06-07
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors (NCT05932862)Exelixis2024-04-03
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (NCT05678673)Exelixis2023-01-01
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma (NCT05144347)Exelixis2022-04-12
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483)Exelixis2021-12-14
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284)Exelixis2021-06-07
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332)Exelixis2021-02-10
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (NCT04446117)Exelixis2020-10-19
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (NCT03937219)Exelixis2019-06-25
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166)Exelixis2019-03-20
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy (NCT03690388)Exelixis2018-10-05
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy (NCT03755791)Exelixis2018-06-10

Track Exelixis automatically

Every clearance here is in the API, with alerts when new ones post.